Introduction to Movantik
Movantik, also known as Moventig in some regions, is a peripheral opioid receptor antagonist (PAMORA) developed by AstraZeneca and Nektar Therapeutics. It is specifically designed to treat opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. Here, we will delve into the market analysis and price projections for this medication.
Market Position and Competition
Movantik holds a significant market share in the PAMORA class, with over 70% market dominance. This leadership position is reinforced by its preferred status in two of the three largest commercial pharmacy benefit managers (PBMs) and a 92% preferred status within Medicare Part D[3].
The competition in this space includes other PAMORAs, such as bevenopran (MK-2402), which is in Phase III development by Cubist Pharmaceuticals, now a subsidiary of Merck & Co.[1]. However, Movantik's established presence and strong market share give it a considerable advantage.
Commercial Performance and Growth
Movantik has shown consistent growth in new prescriptions. In Q2 2022, it experienced a 4% increase in new prescriptions compared to Q1 2022, marking the highest quarterly prescribing volume since RedHill Biopharma acquired the product rights[3].
The PAMORA class as a whole has seen positive growth trends, with a 7% increase in the three months ending August 2022 compared to the same period in the previous year. This growth is expected to continue, benefiting Movantik as the market leader[3].
Pricing and Cost Analysis
The cost of Movantik can vary depending on the pharmacy and the use of discount cards or coupons. Here are some typical prices:
- For a supply of 30 tablets of 25 mg Movantik, the cost can range from $426.30 to $447.14, with an average cost per unit of $14.21 to $14.90[2].
- Using discount cards, such as those from Drugs.com or SingleCare, patients can reduce the cost. For example, with SingleCare, the price for 14 tablets of 25 mg Movantik can be reduced to around $191.68 from the retail price of $242.49[5].
Revenue and Financial Projections
The financial performance of Movantik is substantial, driven by its significant market share and growing prescription rates. Here are some key financial highlights:
- In the deal between Daiichi Sankyo and AstraZeneca, Daiichi Sankyo agreed to pay $200 million upfront and up to $625 million in subsequent sales-related payments for the rights to co-commercialize Movantik in the U.S.[1].
- Nektar Therapeutics, the co-developer, has received substantial milestone payments, including $130 million tied to regulatory milestones and double-digit royalty payments on worldwide net sales[1].
Clinical and Quality of Life Impact
Movantik has demonstrated significant clinical benefits in treating OIC. Studies presented at PAINWeek in September 2022 showed that Movantik provides healthcare-related quality of life (HR-QOL) and clinically meaningful symptom improvements compared to placebo in patients with OIC[3].
Patient Outcomes
The improvement in HR-QOL and symptom management underscores the value of Movantik in patient care. Here is a quote from a study:
"Movantik (naloxegol) provides healthcare-related quality of life (HR-QOL) and clinically meaningful symptom improvements, compared to placebo, in patients with opioid-induced constipation (OIC)"[3].
Market Forecast and Projections
GlobalData provides detailed forecasts for pharmaceuticals, including Movantik. Here are some key points:
- The 17-year drug forecast model by GlobalData evaluates the value of Movantik based on market trends, cash inflows and outflows, and potential success rates for each stage of drug development[4].
Growth Trends
The PAMORA class is expected to continue growing, driven by increasing prescription rates and the expanding use of opioids for chronic pain management. As the market leader, Movantik is poised to benefit significantly from these trends.
Revenue Projections
Given the strong market position and growth trends, Movantik's revenue is projected to remain robust. The deal between Daiichi Sankyo and AstraZeneca, which includes up to $625 million in sales-related payments, indicates the potential for significant revenue generation[1].
Challenges and Risks
While Movantik enjoys a strong market position, there are risks and uncertainties associated with its commercial success. These include:
- Market conditions and competition from other PAMORAs.
- Regulatory changes and potential shifts in healthcare policies.
- The risk that growth in prescriptions may not continue as anticipated[3].
Key Takeaways
- Market Dominance: Movantik holds over 70% of the PAMORA market share and enjoys preferred status in major PBMs and Medicare Part D.
- Clinical Benefits: It provides significant improvements in HR-QOL and symptom management for patients with OIC.
- Financial Performance: Strong revenue projections driven by sales-related payments and royalty agreements.
- Growth Trends: Expected to benefit from the growing PAMORA class and increasing opioid use for chronic pain.
- Pricing: Varies by pharmacy, with discount cards offering significant savings.
FAQs
What is Movantik used for?
Movantik is used to treat opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxatives.
How much does Movantik cost?
The cost of Movantik can range from $426.30 to $447.14 for a supply of 30 tablets of 25 mg, depending on the pharmacy and use of discount cards.
Who developed Movantik?
Movantik was co-developed by AstraZeneca and Nektar Therapeutics.
What is the market share of Movantik?
Movantik holds over 70% of the PAMORA market share.
Are there any generic versions of Movantik available?
No, Movantik is currently available only as a brand name drug, with no generic version available.
Sources
- Genetic Engineering & Biotechnology News: "For Up-to-$825M, Daiichi Sankyo Joins AstraZeneca in Co-Marketing Movantik"
- Drugs.com: "Movantik Prices, Coupons, Copay Cards & Patient Assistance"
- PR Newswire: "RedHill Biopharma Provides H1/22 Highlights and Q3/22 Estimates"
- GlobalData: "Net Present Value Model: Movantik - Market Research Reports"
- SingleCare: "Movantik Coupons & Prices"
